Merit Medical Names Medtronic Veteran Martha Aronson As Next CEO, Projects Strong Outlook

Zinger Key PointsQ2 revenue expected to exceed analyst estimates with up to 14% growth.Analyst reaffirms Buy rating, sets $108 price forecast for MMSI.Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up OnMerit Medical Systems Inc.MMSIannounced a leadership transition on Monday, namingMartha Aronsonas its next President and CEO,effective October 3, 2025.Current CEOFred Lampropoulos, who founded the company in 1987, will continue to serve as Chairman of the Board following the transition.The Utah-based medical technology company also provided early revenue estimates for the second quarter, projecting between $380 million and $384 million in unaudited sales, a year-over-year rise of 12% to 14% compared to the same period in 2024. The analyst consensus estimate is pegged at $372.47 million. Constant currency growth is expected in the range of 11% to 13%.Also Read:FDA Sounds Alarm After 33 Injuries Tied To Medtronic Device MalfunctionFollowing the announcement,Needhamanalyst Mike Matson reiterated a buy rating for Merit Medical Systems and maintained a $108 price forecast.In the first quarter of 2025, Merit Medical Systemsdelivereda strong performance, with revenue climbing to $355.4 million, up 9.8% from the same period last year. On a constant currency basis, organic growth reached 6%, signaling solid underlying demand across its portfolio.Leadership Change Marks New ChapterAronson brings with her a wealth of experience in international healthcare management. She previously held executive roles at companies likeEcolab Inc.ECLandHill-Rom Holdings Inc., and spent nearly two decades in leadership positions atMedtronic plc.MDT.She currently serves on the board ofCONMED CorporationCNMDand has held directorships at several other medical and tech firms. Lead Independent DirectorDr. F. Ann Millnersaid the board was united in choosing Aronson after an exhaustive selection process.Price Action:MMSI shares are trading higher by 2.12% to $93.05 premarket at last check Tuesday.Loading...Loading...Read Next:Palantir Co-Founder Joe Lonsdale Wants A FDA Overhaul With Special Forces-Style AI Team Because China Is Racing To Outpace US In BiotechPhoto by PeopleImages.com – Yuri A via ShutterstockMMSIMerit Medical Systems Inc$93.983.14%Stock Score Locked: Edge Members OnlyBenzinga Rankings give you vital metrics on any stock – anytime.Unlock RankingsEdge RankingsMomentum41.85Growth80.31Quality58.68Value44.47Price TrendShortMediumLongOverviewCNMDConmed Corp$51.93-%ECLEcolab Inc$274.000.82%MDTMedtronic PLC$87.900.26%Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. . .Posted In:EquitiesNewsHealth CareTop StoriesMarketsMoversGeneralAI GeneratedBriefsStories That Matterwhy it's moving